Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Infanrix-IPV + Hib
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Infanrix-IPV + Hib is a pentavalent combination vaccine developed by GSK for the active immunization of infants and toddlers. It provides protection against five major childhood diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis (polio), and invasive diseases caused by Haemophilus influenzae type b (Hib). The vaccine formulation consists of diphtheria toxoid, tetanus toxoid, three purified pertussis antigens (pertussis toxoid, filamentous haemagglutinin, and pertactin), inactivated poliovirus (types 1, 2, and 3), and Hib capsular polysaccharide (polyribosylribitol phosphate) conjugated to tetanus toxoid. It is typically administered as a primary vaccination course in the first year of life, often followed by a booster dose in the second year, to ensure long-term immunity.
- Brand names
- Infanrix-IPV + HibInfanrix-IPV/Hib
- Other names
- DTPa-IPV/HibDTPa-IPV+HibDTPa-IPV-Hib
02
Targets
FHA (Filamentous hemagglutinin)PRNP (Cellular Prion Protein)PRN (Pertactin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on Infanrix-IPV + Hib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Infanrix-IPV + Hib.